BIAF vs. RSLS, OFAL, XBP, GLE, SWAG, WAI, DTST, SCOR, FPAY, and SGRP
Should you be buying bioAffinity Technologies stock or one of its competitors? The main competitors of bioAffinity Technologies include ReShape Lifesciences (RSLS), OFA Group (OFAL), XBP Europe (XBP), Global Engine Group (GLE), Stran & Company, Inc. (SWAG), Top KingWin (WAI), Data Storage (DTST), comScore (SCOR), FlexShopper (FPAY), and SPAR Group (SGRP).
bioAffinity Technologies vs. Its Competitors
bioAffinity Technologies (NASDAQ:BIAF) and ReShape Lifesciences (NASDAQ:RSLS) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, dividends, earnings, risk, profitability, analyst recommendations, institutional ownership and media sentiment.
bioAffinity Technologies currently has a consensus price target of $6.00, indicating a potential upside of 1,841.75%. Given bioAffinity Technologies' higher possible upside, analysts plainly believe bioAffinity Technologies is more favorable than ReShape Lifesciences.
1.6% of bioAffinity Technologies shares are owned by institutional investors. Comparatively, 22.1% of ReShape Lifesciences shares are owned by institutional investors. 16.9% of bioAffinity Technologies shares are owned by company insiders. Comparatively, 0.0% of ReShape Lifesciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
In the previous week, bioAffinity Technologies had 3 more articles in the media than ReShape Lifesciences. MarketBeat recorded 4 mentions for bioAffinity Technologies and 1 mentions for ReShape Lifesciences. ReShape Lifesciences' average media sentiment score of 1.87 beat bioAffinity Technologies' score of 0.19 indicating that ReShape Lifesciences is being referred to more favorably in the news media.
ReShape Lifesciences has a net margin of -48.26% compared to bioAffinity Technologies' net margin of -110.53%. ReShape Lifesciences' return on equity of -251.90% beat bioAffinity Technologies' return on equity.
bioAffinity Technologies has a beta of 2.52, indicating that its share price is 152% more volatile than the S&P 500. Comparatively, ReShape Lifesciences has a beta of 1.16, indicating that its share price is 16% more volatile than the S&P 500.
ReShape Lifesciences has lower revenue, but higher earnings than bioAffinity Technologies. bioAffinity Technologies is trading at a lower price-to-earnings ratio than ReShape Lifesciences, indicating that it is currently the more affordable of the two stocks.
Summary
bioAffinity Technologies and ReShape Lifesciences tied by winning 7 of the 14 factors compared between the two stocks.
Get bioAffinity Technologies News Delivered to You Automatically
Sign up to receive the latest news and ratings for BIAF and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding BIAF and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
bioAffinity Technologies Competitors List
Related Companies and Tools
This page (NASDAQ:BIAF) was last updated on 7/16/2025 by MarketBeat.com Staff
Free BIAF Stock Alerts